|Applications||ELISA, FACS, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB|
|Application Note||We recommend the following starting dilutions: |
For WB: Use at a dilution of 1:100-1:2000.
For FACS: Use at a dilution of 1:400.
For ELISA: Use at a dilution of 1:100-1:2000.
For ICC/IF: Use at a dilution of 1:50-1:200.
For IHC, IHC-Fr, IHC-P: Use at a dilution of 1:10-1:500.
For IP: Use at an assay dependent dilution.
Optimal dilutions/concentrations should be determined by the end user.
|Positive Controls||BT549 cells or HeLa whole cell extract|
(Please refer to the vial label for the specific concentration)|
|Purification||Immunogen affinity purified|
|Full Name||cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)|
|Product Description||Rabbit polyclonal to p14ARF|
|Background||The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF. |
|Synonyms||Multipl, p14ARF, Cyclin dependent kinase inhibitor 2A, TP16, Cyclin dependent kinase 4 inhibitor A, MTS1, Cell cycle negative regulator beta, CDKN2A, CMM2, MLM, Cyclin dependent kinase inhibitor2A, ARF, Cyclin dependent kinase inhibitor P12, Cyclin depend|
|Specificity||Specific for p14ARF.|
|Immunogen||A synthetic peptide made to a portion of human p14ARF (between residues 50-150) .|
|Species Reactivity||Human, Mouse|